APA

Palte M. J., Wehr A., Tawa M., Perkin K., Leigh-Pemberton R., Hanna J., Miller C. & Penner N. (20200625). Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. : Advances in therapy.

Chicago

Palte Michael J, Wehr Angela, Tawa Mark, Perkin Kristopher, Leigh-Pemberton Richard, Hanna Jerome, Miller Catherine and Penner Natasha. 20200625. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. : Advances in therapy.

Harvard

Palte M. J., Wehr A., Tawa M., Perkin K., Leigh-Pemberton R., Hanna J., Miller C. and Penner N. (20200625). Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. : Advances in therapy.

MLA

Palte Michael J, Wehr Angela, Tawa Mark, Perkin Kristopher, Leigh-Pemberton Richard, Hanna Jerome, Miller Catherine and Penner Natasha. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. : Advances in therapy. 20200625.